View Older Stories View More Recent Stories

Sep 9, 2023 06:01PM Bristol Myers Squibb’s Investigational LPA1 Antagonist Reduces Rate of Lung Function Decline in Progressive Pulmonary Fibrosis Cohort of Phase 2 Study
Sep 7, 2023 07:00AM Bristol Myers Squibb Celebrates a Decade of Its Coast 2 Coast 4 Cancer Cross-Country Bike Ride in Support of the V Foundation for Cancer Research
Sep 1, 2023 06:59AM Bristol Myers Squibb to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
Aug 29, 2023 05:31AM Bristol-Myers Squibb (BMY) Announces FDA Approval of Reblozyl for Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions
Aug 28, 2023 10:00PM U.S. FDA Approves Bristol Myers Squibb’s Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions
Aug 28, 2023 11:26AM Bristol-Myers Squibb (BMY) Reports Follow-Up Data from Two Phase 3 Studies of CAMZYOS Demonstrate Consistent and Durable Response
Aug 28, 2023 11:26AM Long-Term Follow-Up Data from Two Phase 3 Studies of CAMZYOS® (mavacamten) Demonstrate Consistent and Durable Response in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)
Aug 25, 2023 10:22AM Retrospective Observational Study Assessing Real-World Clinical Impact of Switching or Continuing Eliquis® or Rivaroxaban Presented at the European Society of Cardiology (ESC) Congress 2023
Aug 23, 2023 07:55AM Bristol Myers Squibb Shares Progress Toward Its Environmental, Social, and Governance Initiatives and Its Health Equity Commitments
Aug 22, 2023 04:18PM Bristol-Myers Squibb (BMY) Receives European Commission Approval for Opdivo as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma
Aug 22, 2023 04:18PM Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma  
Aug 21, 2023 06:59AM Bristol Myers Squibb to Showcase Data Across its Innovative Cardiovascular Portfolio at the European Society of Cardiology Congress 2023
Aug 16, 2023 10:26AM Bristol-Myers Squibb (BMY) Updated Data from TRIDENT-1 Trial Show Durable Efficacy Benefits with Repotrectinib for Patients with Locally Advanced or Metastatic ROS1-Positive NSCLC
Aug 16, 2023 10:19AM Updated Data from TRIDENT-1 Trial Show Durable Efficacy Benefits with Repotrectinib for Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
Aug 10, 2023 07:01AM Bristol Myers Squibb Inducted into the Billion Dollar Roundtable, Expands Supplier Diversity Efforts
Aug 10, 2023 06:59AM Bristol-Myers Squibb (BMY) Enters Into $4 Billion Aggregate Accelerated Share Repurchase Agreements
Aug 10, 2023 06:59AM Bristol Myers Squibb Enters Into $4 Billion Aggregate Accelerated Share Repurchase Agreements
Aug 8, 2023 06:59AM Bristol Myers Squibb Launches Clear Understanding Campaign to Reveal the Plain Truth About Living with Moderate to Severe Plaque Psoriasis
Jul 27, 2023 06:59AM Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
Jul 24, 2023 07:13AM Immatics (IMTX) Announces $35 Million Equity Investment from Bristol Myers Squibb (BMY)
Jul 24, 2023 07:00AM Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb
Jul 21, 2023 06:59AM Bristol-Myers Squibb (BMY) Reports Positive CHMP Opinion Recommending Approval for Opdivo as Adjuvant Treatment
Jul 21, 2023 06:59AM Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma
Jul 12, 2023 06:59AM Bristol Myers Squibb Launches Supporting You with UC, with Women’s World Cup Commentator, Former Professional Soccer Player and Ulcerative Colitis Patient, Rosie White
Jul 11, 2023 06:59AM Bristol-Myers Squibb (BMY) Reports Opdivo with Cisplatin-Based Chemotherapy Shows Overall Survival and Progression-Free Survival Benefit for Cisplatin-Eligible Patients with Unresectable or Metastatic
Jul 11, 2023 06:59AM Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy Shows Overall Survival and Progression-Free Survival Benefit for Cisplatin-Eligible Patients with Unresectable or Metastatic Urothel
Jul 11, 2023 01:50AM Evotec and Bristol Myers Squibb Enter Licence Agreement within Neuroscience Partnership
Jun 29, 2023 07:00AM Bristol-Myers Squibb (BMY) Granted EU Approval for Opdivo with Chemotherapy as Neoadjuvant Treatment
Jun 29, 2023 06:59AM Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Pati
Jun 26, 2023 04:01PM Bristol-Myers Squibb (BMY) Receives European Commission Approval of CAMZYOS (mavacamten), for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy
Jun 26, 2023 04:01PM Bristol Myers Squibb Receives European Commission Approval of CAMZYOS® (mavacamten), for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)
Jun 17, 2023 05:30AM Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) Delivers Deep and Durable Responses in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma in TRANSCEND Clinical Trials Pre
Jun 16, 2023 06:03AM Bristol-Myers Squibb (BMY) Announces FDA Approval of Addition of Positive Data from Phase 3 VALOR-HCM Study to CAMZYOS Label
Jun 15, 2023 08:23PM U.S. Food and Drug Administration Approves Addition of Positive Data from Phase 3 VALOR-HCM Study to CAMZYOS® (mavacamten) Label
Jun 14, 2023 04:16PM Bristol Myers Squibb Announces Dividend
Jun 8, 2023 04:16PM Bristol-Myers Squibb (BMY) Receives FDA Approval of New Cell Therapy Manufacturing Facility in Devens, Massachusetts
Jun 8, 2023 04:16PM Bristol Myers Squibb Receives U.S. FDA Approval of New State-of-the-Art Cell Therapy Manufacturing Facility in Devens, Massachusetts
Jun 8, 2023 06:59AM Bristol Myers Squibb to Report Results for Second Quarter 2023 on July 27, 2023
Jun 4, 2023 08:00AM Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-
Jun 1, 2023 06:59AM Bristol Myers Squibb to Participate in Upcoming Investor Conferences
May 31, 2023 06:59AM Bristol Myers Squibb to Hold R&D Day on September 14
May 30, 2023 09:24AM Bristol Myers Squibb to Present Late-Breaking Data for Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma at 2023 International Conference on Ma
May 30, 2023 07:00AM Bristol-Myers Squibb (BMY) Announces FDA Accepts for Priority Review Application for Repotrectinib for the Treatment of Patients with Locally Advanced or Metastatic ROS1-Positive NSCLC
May 30, 2023 06:59AM U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Repotrectinib for the Treatment of Patients with Locally Advanced or Metastatic ROS1-Positive Non
May 26, 2023 08:10AM Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion Recommending Approval for Opdivo with Chemotherapy
May 26, 2023 08:10AM Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Rec
May 25, 2023 05:05PM Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) is First and Only CAR T to Deliver Deep and Durable Efficacy in Pivotal Multicenter Trial in Relapsed or Refractory Chronic Lymphocytic Leu
May 25, 2023 05:03PM Bristol-Myers Squibb (BMY) to Present First Results at ASCO and EHA from Phase 3 COMMANDS Study of Reblozyl
May 25, 2023 05:00PM Bristol Myers Squibb to Present First Results at ASCO and EHA from Phase 3 COMMANDS Study of Reblozyl® (luspatercept-aamt) in First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic
May 22, 2023 11:01AM Bristol-Myers Squibb's (BMY) Investigational LPA1 Antagonist Reduces the Rate of Lung Function Decline in Patients with Idiopathic Pulmonary Fibrosis
View More Recent Stories View Older Stories